Finally, the summer is over. This means excitement to all the football fans. NFL season officially started last night with the Superbowl champion, the New England Patriots hosting the Kansas City Chiefs. More games and more excitement is on the horizon. What does this have to do with BioDiscovery?BioDiscovery is starting its new season with new product releases at ASHG in mid-October. It is bound to bring excitement to the genetic testing field, as NFL does to the football fans. Since NGS (next-generation sequencing) is still a hot topic, people will see lots of new things on this front in BioDiscovery's NxClinical 4.0 version. As usual, we will showcase its copy number analysis prowess with its 4th-generation method to derive copy number from NGS.
Below is a teaser. Can anyone tell from this whole genome view what platform, array or NGS, this sample was run on? The answer is NGS. A deeper question, was it whole genome sequencing (WGS) or targeted panel?
The answer is targeted panel. As a matter of fact, it is an FFPE cancer sample run on a 300+ gene panel. This analysis method takes in reads from both target and off-target regions, thus covers the entire genome to result in copy number calls for large segments, such as the whole chromosome (e.g. Chr7 loss and Chr8 gain) or the p or q arm (e.g. 16q or 17p).
BioDiscovery will be exhibiting at ASHG in booth #935. Please come to visit us and let us show you all the exciting new features in our NxClinical 4.0.